Greenland Mines Secures Canadian Patent for Klotho Gene Therapy Technology

Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.

According to the press release, the Canadian patent expands Greenland Mines’ intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. The company noted that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The full release is available at https://ibn.fm/x2pHA.

This development is significant because it strengthens Greenland Mines’ position in the emerging field of gene therapy for neurodegenerative conditions, which represent a substantial unmet medical need. The issuance of a Canadian patent not only provides protection in a key market but also validates the company’s technology platform. With manufacturing milestones approaching, Greenland Mines is transitioning from research and development to clinical-stage operations, which could accelerate the path toward potential therapies for diseases affecting millions worldwide.

The company operates two divisions: mining and biotech. In biotech, Klotho’s KLTO-202 is targeting ALS as its primary indication. The mining division focuses on the Skaergaard Project in Greenland and the Sarfartoq rare earths project. The company’s strategy centers on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and midstream processing opportunities. More information can be found in the company’s newsroom at https://ibn.fm/GRML.

Forward-looking statements in the release are subject to risks and uncertainties, as detailed in the company's SEC filings. The company undertakes no duty to update this information unless required by law.